Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265219 | 0.94 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL18499075 | 0.94 | CA14 (0.54) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL31216205 | 0.88 | CA14 (0.49) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL21068864 | 0.88 | CA14 (0.52) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL25473057 | 0.88 | CA14 (0.53) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL6510544 | 0.85 | HDAC1 (0.49) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL16486684 | 0.82 | CA14 (0.49) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL5024808 | 0.81 | TSHR (0.45) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL25756187 | 0.81 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2KDM5A | |
| SCHEMBL23765859 | 0.81 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269943-A1 | RADIOLABELED ANNEXINS | UNIVERSITY OF WASHINGTON (US) | 2011-11-03 | — | — | US | disclosed |
| US-7744853-B2 | Radiolabeled annexins | PONIARD PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7115248-B2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060029545-A1 | Radiolabeled annexins | NEORX CORPORATION, REGENTS OF THE UNIVERSITY OF MICHIGAN | 2006-02-09 | — | — | US | disclosed |
| US-6908903-B1 | Cluster clearing agents | ALETHEON PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050036948-A1 | Radiolabeled annexins | NEORX CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-1426062-A2 | Radiolabeled annexins | NEORX CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0918547-B1 | RADIOLABELED ANNEXINS | NEORX CORP (US) | 2004-03-10 | — | — | EP | disclosed |
| US-20030220233-A1 | Radiolabeled annexins | NEORX CORPORATION | 2003-11-27 | — | — | US | disclosed |
| US-20020137672-A1 | Radiolabeled annexins | KASINA SUDHAKAR (US) | 2002-09-26 | — | — | US | disclosed |
| US-6172045-B1 | COMPLEX CONTAINING 1-DESOXY-1-THIO-N-ACETYLGALACTOSAMINE | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
| US-6171577-B1 | ACCESSIBLE SULFHYDRYL GROUP; AND HEXOSE MOIETY RECOGNIZED BY A MAMMALIAN LIVER RECEPTOR, WHEREIN THE HEXOSE MOIETY IS CONJUGATED TO THE ANNEXIN. | NEORX CORPORATION | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060029545-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA14 740/4885HDAC6 2939/4885HDAC1 4383/4885 |
| US-20050036948-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA14 740/4885HDAC6 2939/4885HDAC1 4383/4885 |
| US-20110269943-A1 | RADIOLABELED ANNEXINS | ANXA11, ANXA1, ANXA3 | CA14 740/4885HDAC6 2939/4885HDAC1 4383/4885 |
| US-20020137672-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA14 740/4885HDAC6 2939/4885HDAC1 4383/4885 |
| US-20030220233-A1 | Radiolabeled annexins | ANXA11, ANXA1, ANXA3 | CA14 740/4885HDAC6 2939/4885HDAC1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.